has been studied in more than 5,500 patients in 14 clinical trials with data up to 192 weeks.
Doravirine versus ritonavir-boosted darunavir
in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Drugs that inhibit CYP3A4 [1, 6, 7, 11, 12], among them darunavir
and other protease inhibitors, can raise the ergotamine concentration to toxic levels, even when ergotamine is administered at low doses [2, 6] (in this case patient was not taking any other medication which could interact with CYP3A4).
ART rejimi n=95 (%) TDF/FTC + LPV/r 45 (%47,4) TDF/FTC + DTG 16 (%16,8) TDF/FTC + EVG/c 15 (%15,8) TDF/FTC + RAL 13 (%13,7) TDF/FTC + EFV 5 (%5,3) TDF/FTC + DRV/ r 1 (%1,1) c: Kobisistat, DRV: Darunavir
, DTG: Dolutegravir, EFV: Efavirenz, EVG: Elvitegravir, FTC: Emtrisitabin, LPV: Lopinavir, RAL: Raltegravir, r: Ritonavir, TDF: Tenofovir disoproksil fumarat Tablo 3.
The preferred regimens for starting treatment in the major international treatment guidelines have gradually moved towards an NRTI backbone of tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC), tenofovir alafenamide/FTC (TAF/FTC) or abacavir/lamivudine (ABC/3TC) plus either the protease inhibitor (PI) darunavir
(DRV) boosted by either ritonavir (r) or cobicistat (c), or the integrase inhibitors raltegravir (RAL), elvitegravir (ELV) or dolutegravir (DTG) or the non-nucleoside reverse transcriptase inhibitors rilpivirine (RPV) or efavirenz (EFV)--see EACS Guidelines.
(25) Even when boosted with ritonavir, the currently favored PIs darunavir
(39,40) and atazanavir (40,41) upset lipids less than previous PIs.
Given the patient's clinical instability and unresponsiveness to supportive treatment, ART was empirically initiated with tenofovir/emtricitabine, darunavir
, and ritonavir.
She had been taking antiretroviral drugs including tenofovir, emtricitabine, and boosted darunavir
thereafter and achieved virological control after 6 months of therapy.
Incidence of dyslipidemia was found to be higher with LPV/r use than with darunavir
and atazanavir use .
(DRV) is a once-daily second-generation protease-inhibitor [1, 2] that is administered with low-dose ritonavir (DRV/r) and two nucleoside reverse transcriptase inhibitors (NRTI) for treatment of HIV infection.
PI-based regimen Darunavir
(Prezista) and ritonavir (Norvir) plus tenofovir disoproxil fumarate/emtricitabine (Truvada).
All subjects were on antiretroviral regimens based upon either darunavir
(Prezista), atazanavir (Reyataz), raltegravir (Isentress), or dolutegravir (Tivicay).